Piet Ost
@piet_ost
Radiation Oncologist, Iridium Network, GZA Ziekenhuizen, Antwerp. Associate professor Ghent University, Belgium.
📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity
Finally, a killer application for Y-90 FAPI theranostics? Near complete metabolic responses in 3 patients with treatment refractory solitary fibrous tumors. Ga-68 FAPI had high SUVs (117, 41, 31) with concordant FDG uptake. jnm.snmjournals.org/content/early/… @SNM_MI Wonderful work from…
Thank you so much!🙏 My goal is to demystify rad onc (& GI onc). Channel link is here btw. Planning for more videos to come! youtube.com/@NinaNSanfordMD
One of our stellar @ASCO LDP mentees this year, @NiuSanford @utswcancer, has put together a phenomenal series of online lectures on @YouTube (totally free!) detailing different aspects of #radonc. There is certainly some focus on GI onc, her specialty, but I think every #hemeonc…
6/ We included 799 pts on modern, MRI-driven AS across 3 centers Two 🔑 features explain nearly all risk of AS failure in multivar analysis: 1️⃣ cribriform morphology → HR 13‼️ 2️⃣ PI-RADS 3-5 → HR 5
In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. @EurUrolOncol @DrSpratticus @OncoAlert @APCCC_Lugano @Uroweb…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…
NEW PAPER in @bmj_latest "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide" --> bmj.com/content/390/bm… #methodologymatters
Mechanism of hormone therapy for prostate cancer #pcsm
Dit moet meer onder de aandacht komen. Halfbakken onderzoek, belastinggeld dat massaal aan uitgeverijen gegeven wordt. De academische wereld zelf vindt de kwaliteit van wetenschappelijke papers nog niet slecht genoeg, want die doen gewoon door. theguardian.com/science/2025/j…
Well done @ERunswickBMA on @BBCr4today - clear explanation as to why resident doctors need pay restoration Despite @bbcnickrobinson constantly interrupting and not letting you finish a single sentence Resident doctors deserve pay restoration to 2008 levels at the very least
@ChadTangMD & I happy to report: ph2 basket EXTEND-OP trial has enrolled and randomized 150 patients in the last year since opening: - 7 histology-specific baskets - Oligoprogressive dz randomized to: ☢ Local Tx + continued same-line systemic, versus 💊Switching systemic Tx
Excited to share our newest paper on digital pathology AI biomarkers in prostate cancer RT. In this work we: ▶️performed a systematic review ▶️checked ongoing trials ▶️collected an expert consensus sciencedirect.com/science/articl… Thanks @RO_GreenJournal for accepting this work
The 10-year results of the HYPO-RT-PC trial, presented at #ESTRO25, confirm that ultra-hypofractionated #radiotherapy is a safe, effective option for localised #prostatecancer — with strong evidence and long-term follow-up to back it up. 👉 bit.ly/3T3jc0X
5/5 🔧 Try it yourself: Shiny app estimates replication probability from HR and 95% CI of oncology phase 3 RCTs ➡️ alexandersherry.shinyapps.io/shinyapp_repli… Take-home: Trust the sign, test the magnitude, and treat marginal p values as provisional regardless of whether or not they crossed 0.05.
3/5 ⚠️ Statistical “significance” is fragile A trial that yields p = 0.05 has only ≈ 43% probability of another identical trial also beating p ≤ 0.05 (60% at 0.01, 77% at 0.001). Borderline results ≠ final word.
Some ask if patients with limited metastatic disease can be cured. The answer is clearly yes. We’ve known that since the 1930’s, and it was very clearly articulated in this book from the 1960s. In 2026 we’ll report the final outcomes from SABR-COMET, 10 years after closure.
Can metformin boost survival in metastatic hormone-sensitive prostate cancer? 🔑 : A win for metabolic health, but not a game-changer (yet). ❌ No significant OS benefit (HR 0.91, p=0.15) ✅ Reduced ADT-related metabolic side effects 💊 Safe & well-tolerated (mostly GI issues)…
Brilliant definition of a way to use SBRT/SRS as a strategic tool in cancer treatment management. sciencedirect.com/science/articl…
Happy to introduce something different from classical curative or palliative radiotherapy: Strategic radiotherapy: a new proof of concept sciencedirect.com/science/articl… @ESTRO_RT @SapienzaRoma
🚨Happy to share that I'm launching a new study called RAPSTAR - the first randomised, multicentre phase III trial comparing RAPN vs #SABR in patients who are candidates for surgery. Designed and led in 🇵🇱, just got funding from @AgencjaBadanMed and will start accrual soon!
Beperking van supplementen kan mutualiteiten tot 100 miljoen euro opleveren @bvastweets @DeClercqLuc @IrinaDeKnop @NataliEggermont @valerievanpeel @ASGB_KARTEL despecialist.eu/nl/nieuws/bero…